Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.
Read Full NewsNon-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy
1.
Error on the MGUS-Autoimmune Disease Association.
2.
New imaging technique identifies glioblastoma patients who would benefit from immunotherapy
3.
Muscular strength and good physical fitness linked to lower risk of death in people with cancer
4.
Cancerous breast tissue glows in new AI-enhanced MRI images
5.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
1.
Understanding the Role of CA 19-9 in Cancer Diagnosis and Treatment
2.
Don't Ignore Your Vision Loss: What You Need to Know About Amaurosis Fugax
3.
Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights
4.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
5.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Thromboprophylaxis In Medical Settings- An Update
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
4.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
5.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge